The European Commission Has Approved AstraZeneca's Voydeya (Danicopan) As An Add-on To Ravulizumab Or Eculizumab For Paroxysmal Nocturnal Hemoglobinuria Patients Who Have Residual Hemolytic Anemia
歐盟委員會已批准阿斯利康的Voydeya（Danicopan）作爲Ravulizumab或Eculizumab的附加組件，用於有殘留溶血性貧血的陣發性夜間血紅蛋白尿症患者